A 2.5-Year Within-Patient Evolution of Pseudomonas aeruginosa Isolates with In Vivo Acquisition of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistance upon Treatment-Reference-Cited by-同舟云学术

A 2.5-Year Within-Patient Evolution of Pseudomonas aeruginosa Isolates with In Vivo Acquisition of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistance upon Treatment

Published:2019-12 Issue:12 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Boulant Thibaud¹²,Jousset Agnès B.¹²³,Bonnin Rémy A.¹²,Barrail-Tran Aurélie⁴,Borgel Adrien¹²³,Oueslati Saoussen¹²,Naas Thierry¹²³^ORCID,Dortet Laurent¹²³^ORCID

Affiliation:

1. EA7361 Structure, dynamic, function and expression of broad spectrum β-lactamases, Paris-Sud University, Paris Saclay University, Le Kremlin-Bicêtre, France

2. Faculty of Medicine, Paris-Sud University, Paris Saclay University, Le Kremlin-Bicêtre, France

3. Department of Bacteriology-Hygiene, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France

4. Department of Pharmacy, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France

Abstract

Ceftolozane-tazobactam is considered to be a last-resort treatment for infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa . Although resistance to this antimicrobial has been described in vitro , the development of resistance in vivo has rarely been reported. Here, we describe the evolution of resistance to ceftolozane-tazobactam of P. aeruginosa isolates recovered from the same patient during recurrent infections over 2.5 years.

Funder

Agence Nationale de la Recherche

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01637-19

Reference24 articles.

1. Pseudomonas aeruginosainfection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches

2. Metallo beta lactamases inPseudomonas aeruginosaand Acinetobacter species

3. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium

4. Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Alternatives for Experimental Adaptation to Colistin in Three Pseudomonas aeruginosa Lineages;Antibiotics;2024-05-15

2. Ecological and evolutionary mechanisms driving within-patient emergence of antimicrobial resistance;Nature Reviews Microbiology;2024-04-30

3. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling;Antimicrobial Agents and Chemotherapy;2023-10-18

4. WHY SO SENSITIVE? THE IN VIVO LIFE OF PSEUDOMONAS AERUGINOSA;CHEST;2023-10

5. Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance;Antimicrobial Agents and Chemotherapy;2023-08-17